Timothy KinyanjuiWirichada Pan-NgumSompob SaralambaSylvia TaylorLisa WhiteD. James NokesGlaxoSmithKline Pharmaceuticals SA/NVWellcome Trust Research Laboratories NairobiThe University of WarwickMahidol UniversityNuffield Department of Clinical MedicineUniversity of ManchesterPeak AI2020-03-262020-03-262020-04-09Vaccine: X. Vol.4, (2020)259013622-s2.0-85079852816https://repository.li.mahidol.ac.th/handle/20.500.14594/53561© 2020 The Author(s) Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/j.jvacx.2020.100055